10-K: OmniAb, Inc. Reports Full Year 2023 Results, Highlights Platform Growth and Strategic Investments

OmniAb, Inc. reported its full year 2023 results, showcasing growth in partnerships and programs, while also detailing strategic investments in technology and infrastructure.

Summary

• OmniAb, Inc. reported a total revenue of $34.2 million for the year ended December 31, 2023, a decrease from $59.1 million in 2022.
• The company's net loss for 2023 was $50.6 million, compared to a net loss of $22.3 million in 2022.
• License and milestone revenue decreased to $20.7 million in 2023 from $38.9 million in 2022, primarily due to a large milestone payment in 2022.
• Service revenue also decreased to $12.2 million in 2023 from $18.8 million in 2022, due to the completion of certain programs.
• The company's operating expenses increased to $103.6 million in 2023 from $85.7 million in 2022, driven by increased research and development and general and administrative costs.
• As of December 31, 2023, OmniAb had 77 active partners, 325 active programs, and 32 active clinical programs and approved products.
• The company's cash, cash equivalents, and short-term investments totaled $87.0 million as of December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive growth in partnerships and programs, the significant decrease in revenue and increase in net loss, along with the risks outlined, temper the overall sentiment. The company is making strategic investments, but the financial results are concerning.

Positives

• The company has a diverse range of partners, including pharmaceutical, biotechnology, and academic organizations.
• OmniAb's technology platform is designed to increase the probability of success, reduce costs, and shorten development timelines for partners.
• The company has a modular technology platform that can be customized to meet partners' specific needs.
• The company has a four-species platform, which is unique in the industry.
• The company has made strategic investments in technology acquisitions and internal innovation.

Negatives

• The company experienced a significant decrease in revenue from $59.1 million in 2022 to $34.2 million in 2023.
• The company's net loss increased from $22.3 million in 2022 to $50.6 million in 2023.
• The company's operating expenses increased significantly in 2023.
• The company is dependent on its partners' efforts for the progression, clinical development, and commercialization of therapeutic candidates.

Risks

• The company may not be able to generate sufficient revenue to achieve and maintain profitability.
• The company's operating results may fluctuate significantly, making future results difficult to predict.
• The company's commercial success depends on the acceptance of its technology by new and existing partners.
• The company's future success is dependent on the eventual approval and commercialization of products developed by its partners.
• The company faces intense competition in the market for antibody discovery technologies.
• The company relies on third parties for various services, including hosting animal colonies and supplying laboratory equipment.
• The company may not be able to obtain and maintain sufficient intellectual property protection for its platform and technology.
• The company relies on in-licenses from third parties, and losing these rights could negatively impact the business.
• Unstable market and economic conditions may have adverse consequences on the company's business and stock price.
• The market price of the company's stock and warrants is likely to be highly volatile.

Future Outlook

The company believes its existing cash and cash equivalents, together with anticipated cash flows from operations, will be sufficient to meet working capital and capital expenditure needs over at least the next 12 months. The company expects to continue to incur losses for the foreseeable future and anticipates these losses will increase substantially as it invests in research and development activities.

Management Comments

• The company aims to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies.
• The company's strategy includes enabling the discovery of high-quality antibody candidates, expanding existing partnerships, increasing the number of partnerships, and further technological differentiation through innovation.
• The company believes its long-term value will be driven by royalties from partnered programs.

Industry Context

The document highlights the growing market for antibody therapeutics and the increasing number of approvals, but also notes the fragmentation and inefficiencies in current discovery approaches. OmniAb positions itself as a solution to these challenges by offering a comprehensive, biologically-driven technology platform.

Comparison to Industry Standards

• The document cites a BIO study indicating that monoclonal antibodies have a 12.1% likelihood of receiving market authorization from the start of Phase 1 clinical trials, which is higher than the success rate of small molecule modalities at 7.5%.
• The document also references data from the Antibody Society, stating that over 90% of approved antibody drugs are derived from natural immune systems.
• The document mentions that EvaluatePharma data indicates that monoclonal antibodies have represented the majority of the top 10 bestselling drugs over the last five years.
• The document notes that in 2022, approved antibody-based therapeutics accounted for approximately $240 billion in sales, according to data published by Clarivate Analytics Cortellis, and that antibody-based therapeutic sales are expected to surpass $300 billion by 2027.
• The document states that the number of antibodies in the clinic has increased from 572 in 2018 to 1,212 in 2023, an estimated 20% CAGR.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and increase in net loss.
• Employees may be affected by the company's financial performance and any potential restructuring.
• Partners may be impacted by the company's ability to continue to invest in its technology platform.
• Customers may be affected by the company's ability to deliver on its promises.

Next Steps

• The company intends to continue to identify and capture new opportunities with existing partners.
• The company plans to continue to gain new customers through increased business development activities and technological expansion.
• The company intends to continue to invest in enabling technologies and evaluate strategic technology acquisitions.

Key Dates

Keywords

antibody discovery, therapeutic antibodies, transgenic animals, biologics, drug development, single-cell screening, AI, machine learning, licensing, pharmaceutical, biotechnology